PDCs (Peptide Drug Conjugates) is a new type of conjugated drug. The drug conjugates are comprised of three modules: payload, linker, and carrier. Schematic structure of receptor targeting drug conjugates. Peptides can provide some unparalleled advantages to some extent, including enhanced tumor penetration, reduced immunogenicity, and lower production costs. As a cytotoxic drug, ADC may have serious toxicity and hinder its further treatment, the complex structure of ADC leads to high production costs, and the large molecular weight limits the ability to penetrate solid tumors, thereby limiting its efficacy. Although the ADC therapies continues to make progress, there are still some problems with these therapies. To date, there are 12 ADCs drugs approved by the FDA. We have already witnessed the success of antibody-conjugated drugs (ADC). Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. Antibody-drug conjugates (ADCs) are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |